Opendata, web and dolomites

RESTORE SIGNED

NEURONAL SELF-RENEWAL BY ANTIGEN-SPECIFIC TOLERIZATION IN MULTIPLE SCLEROSIS REINSTALLING THE BALANCE BETWEEN INFLAMMATION AND REGENERATION

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RESTORE project word cloud

Explore the words cloud of the RESTORE project. It provides you a very rough idea of what is the project "RESTORE" about.

place    multidisciplinary    context    therapeutic    action    sclerosis    joins    chronic    nervous    remaining    safeguarding    damaging    centers    pathogens    healthcare    proof    inflammation    cure    safety    repair    autoreactive    renewal    reducing    efficacy    500    thereby    young    multiple    coordinated    patient    clinic    safely    therapy    capacity    immunity    disabling    trials    traumatic    countries    approvals    restore    neurological    regulatory    neurodegeneration    protective    nl    central    consented    team    outcome    correlates    efforts    compare    accessibility    network    first    monitoring    clinical    cells    toldc    centralized    cell    inflammatory    biobanking    innovative    immunomonitoring    patients    drive    radiological    bm1305    inducing    tolerance    center    breakthrough    assaults    reactions    es    neurodegenerative    additional    untreatable    self    disease    immune    cancer    restoring    ms    single    dendritic    data    ger    neuronal    lives    adults    practicality    balance    antigen    suffering    hypothesize    collaborative    people    mri   

Project "RESTORE" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT ANTWERPEN 

Organization address
address: PRINSSTRAAT 13
city: ANTWERPEN
postcode: 2000
website: www.ua.ac.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website https://www.h2020restore.eu/
 Total cost 5˙357˙032 €
 EC max contribution 5˙357˙032 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) coordinator 911˙176.00
2    INSTITUT CATALA DE LA SALUT ES (BARCELONA) participant 1˙170˙212.00
3    Stichting Sanquin Bloedvoorziening NL (Amsterdam) participant 911˙250.00
4    UNIVERSITAIR ZIEKENHUIS ANTWERPEN BE (EDEGEM) participant 660˙056.00
5    UNIVERSIDAD DE NAVARRA ES (PAMPLONA) participant 625˙000.00
6    ICOMETRIX NV BE (LEUVEN) participant 530˙500.00
7    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER DE (MUENSTER) participant 363˙837.00
8    STICHTING LYGATURE NL (UTRECHT) participant 185˙000.00

Map

 Project objective

Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous system for which no cure is currently available. It is the leading cause of non-traumatic disabling neurological disease in young adults with more than 500,000 people affected in Europe. As chronic inflammatory processes drive the neurodegeneration, we hypothesize that improved clinical outcome can be achieved by restoring the balance between inflammation and the remaining capacity of neuronal self-renewal. In this context, cell therapy that specifically targets the damaging immune reactions that cause MS, thereby reducing the autoreactive, inflammatory assaults in MS without affecting protective immunity against pathogens and cancer, can be a promising approach to allow for more repair. Recently, we set-up a collaborative network of European centers working in cell therapy (COST Action BM1305). From this, a multidisciplinary team from four different EU countries (B, ES, NL and GER) with two additional partners now aims to safely reach the next level of testing and joins efforts to bring antigen-specific cell therapy for MS to the clinic. Our objectives are to evaluate safety, clinical practicality and demonstrate first proof-of-principle of therapeutic efficacy of antigen-specific tolerance-inducing dendritic cells (tolDC) in MS patients in two single-center clinical trials. All regulatory approvals are already in place. Coordinated patient monitoring and centralized MRI monitoring, including radiological correlates of neurodegeneration, and immunomonitoring will enable us to directly compare results between trials and enable consented biobanking, data safeguarding and accessibility to support future efforts in the field of MS therapy. ReSToRe focuses on the advancement of an innovative cell therapy approach with the potential to improve the lives of patients suffering from MS, a currently untreatable disease. This would represent a breakthrough for healthcare in MS.

 Deliverables

List of deliverables.
Certificates of clinical training Documents, reports 2019-08-30 14:59:36

Take a look to the deliverables list in detail:  detailed list of RESTORE deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Willekens B, Presas-Rodríguez, Mansilla M, Derdelinckx J, Lee W-P, Nijs G, De Laere M, Wens I, Cras P, Parizel PM, Van Hecke W, Ribbens A, Billiet T, Adams G, Couttenye M, Navarro-Barriuso J, Teniente-Serra A, Quirant-Sánchez B, López-Díaz de Cerio A, Inogés S, Prósper F, Kip A, Verheij H, Gross CC, Wiendl H, van Ham SM, ten Brinke A, Barriocanal AM, Massuet-Vilamajó A, Hens N, Berneman Z,
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonized study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration
published pages: , ISSN: 2044-6055, DOI:
BMJ Open accepted for publication 23/7/2 2019-09-05
2018 Barbara Willekens, Nathalie Cools
Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis
published pages: 401-410, ISSN: 1172-7047, DOI: 10.1007/s40263-018-0518-4
CNS Drugs 32/5 2019-09-05
2019 Anja ten Brinke, Marc Martinez-Llordella, Nathalie Cools, Catharien M. U. Hilkens, S. Marieke van Ham, Birgit Sawitzki, Edward K. Geissler, Giovanna Lombardi, Piotr Trzonkowski, Eva Martinez-Caceres
Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective
published pages: , ISSN: 1664-3224, DOI: 10.3389/FIMMU.2019.00181
Frontiers in Immunology 10 2019-09-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESTORE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESTORE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HEADSpAcE (2019)

Translational studies of HEAD and neck cancer in South America and Europe

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More